JP2007501800A - レチノイドリガンドを用いて悪液質を処置するための方法 - Google Patents

レチノイドリガンドを用いて悪液質を処置するための方法 Download PDF

Info

Publication number
JP2007501800A
JP2007501800A JP2006522776A JP2006522776A JP2007501800A JP 2007501800 A JP2007501800 A JP 2007501800A JP 2006522776 A JP2006522776 A JP 2006522776A JP 2006522776 A JP2006522776 A JP 2006522776A JP 2007501800 A JP2007501800 A JP 2007501800A
Authority
JP
Japan
Prior art keywords
alkyl
cancer
group
carbon atoms
carbons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006522776A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007501800A5 (enExample
Inventor
チアン，クアン，リアン
ユアン，ヤン−ダー
チャンドララトナ，ロシャンタ，エイ．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of JP2007501800A publication Critical patent/JP2007501800A/ja
Publication of JP2007501800A5 publication Critical patent/JP2007501800A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
JP2006522776A 2003-08-07 2004-08-06 レチノイドリガンドを用いて悪液質を処置するための方法 Pending JP2007501800A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49313803P 2003-08-07 2003-08-07
US53373403P 2003-12-31 2003-12-31
PCT/US2004/025564 WO2005013949A2 (en) 2003-08-07 2004-08-06 Method for treating cachexia with retinoid ligands

Publications (2)

Publication Number Publication Date
JP2007501800A true JP2007501800A (ja) 2007-02-01
JP2007501800A5 JP2007501800A5 (enExample) 2007-09-20

Family

ID=34138739

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006522776A Pending JP2007501800A (ja) 2003-08-07 2004-08-06 レチノイドリガンドを用いて悪液質を処置するための方法

Country Status (5)

Country Link
EP (1) EP1653939A2 (enExample)
JP (1) JP2007501800A (enExample)
AU (1) AU2004263156B2 (enExample)
CA (1) CA2535260A1 (enExample)
WO (1) WO2005013949A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014527083A (ja) * 2011-09-15 2014-10-09 アリゾナ ボード オブ リージェンツ， ア ボディー コーポレイト オブ ザ ステート オブ アリゾナ， アクティング フォー アンド オン ビハーフ オブ アリゾナ ステート ユニバーシティー 治療用化合物
JP2019507777A (ja) * 2016-03-10 2019-03-22 アイオー セラピューティクス インコーポレイテッド Ｒｘｒアゴニストおよび甲状腺ホルモンの組み合わせでの自己免疫疾患の治療
JP2019511492A (ja) * 2016-03-10 2019-04-25 アイオー セラピューティクス インコーポレイテッド Ｒｘｒアゴニストおよび甲状腺ホルモンの組み合わせでの筋肉障害の治療

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT1937244T (lt) 2005-09-30 2018-11-12 Io Therapeutics, Llc Vėžio gydymas specifiniais rxr agonistais
EP2056805B1 (en) * 2006-08-16 2011-05-25 Action Medicines, S.L. Use of 2, 5-dihydroxybenzene derivatives for the treatment of tissue reactive diseases
WO2011006157A2 (en) * 2009-07-10 2011-01-13 Case Western Reserve University Rxr agonist compounds and methods
EP2556827A1 (en) * 2011-08-11 2013-02-13 Acadia Pharmaceuticals Inc. Treatment of neurodegenerative diseases
CN110151745A (zh) 2011-12-13 2019-08-23 Io治疗公司 使用rxr激动剂的自身免疫紊乱的治疗
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
RU2720237C2 (ru) 2013-11-18 2020-04-28 Форма Терапеутикс, Инк. Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
BR122019007990B1 (pt) 2013-11-18 2021-05-04 Forma Therapeutics, Inc Composto, e, composição farmacêutica
US10231947B2 (en) 2017-01-23 2019-03-19 Arizona Board Of Regents On Behalf Of Arizona State University Isochroman compounds and methods of use thereof
US10238655B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Dihydroindene and tetrahydronaphthalene compounds
US10238626B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
EP3684348A4 (en) 2017-09-20 2021-08-18 IO Therapeutics, Inc. TREATMENT OF DISEASES WITH ETERS FROM SELECTIVE RXR AGONISTS
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
EP4444287A4 (en) 2021-12-07 2025-05-28 Io Therapeutics, Inc. USE OF AN RXR AGONIST AND TAXANES FOR THE TREATMENT OF HER2+ CANCER
KR20240115316A (ko) 2021-12-07 2024-07-25 아이오 테라퓨틱스, 인크. 약물 내성 her2+ 암 치료에서의 rxr 작용제의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09512830A (ja) * 1994-08-10 1997-12-22 エフ・ホフマン−ラ ロシュ アーゲー レチノイン酸ｘ受容体リガンド
JPH11507053A (ja) * 1995-06-06 1999-06-22 アラーガン レチノイド様生物学的活性を有する２，４−ペンタジエン酸誘導体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6320074B1 (en) * 1992-04-22 2001-11-20 Ligand Pharmaceuticals Incorporated Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
IL116259A (en) * 1994-12-19 2000-07-16 American Cyanamid Co Analogs of 9-cis retinoic acid and their use
US5917082A (en) * 1995-06-06 1999-06-29 Allergan Sales, Inc. 2,4-pentadienoic acid derivatives having retinoid-like biological activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09512830A (ja) * 1994-08-10 1997-12-22 エフ・ホフマン−ラ ロシュ アーゲー レチノイン酸ｘ受容体リガンド
JPH11507053A (ja) * 1995-06-06 1999-06-22 アラーガン レチノイド様生物学的活性を有する２，４−ペンタジエン酸誘導体

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014527083A (ja) * 2011-09-15 2014-10-09 アリゾナ ボード オブ リージェンツ， ア ボディー コーポレイト オブ ザ ステート オブ アリゾナ， アクティング フォー アンド オン ビハーフ オブ アリゾナ ステート ユニバーシティー 治療用化合物
JP2019507777A (ja) * 2016-03-10 2019-03-22 アイオー セラピューティクス インコーポレイテッド Ｒｘｒアゴニストおよび甲状腺ホルモンの組み合わせでの自己免疫疾患の治療
JP2019511492A (ja) * 2016-03-10 2019-04-25 アイオー セラピューティクス インコーポレイテッド Ｒｘｒアゴニストおよび甲状腺ホルモンの組み合わせでの筋肉障害の治療
CN115227826A (zh) * 2016-03-10 2022-10-25 Io治疗公司 Rxr激动剂和甲状腺激素在制备用于治疗自身免疫疾病的药物中的用途
CN115227825A (zh) * 2016-03-10 2022-10-25 Io治疗公司 Rxr激动剂和甲状腺激素在制备用于治疗自身免疫疾病的药物中的用途
JP7169646B2 (ja) 2016-03-10 2022-11-11 アイオー セラピューティクス インコーポレイテッド Ｒｘｒアゴニストおよび甲状腺ホルモンの組み合わせでの自己免疫疾患の治療
JP7169647B2 (ja) 2016-03-10 2022-11-11 アイオー セラピューティクス インコーポレイテッド Ｒｘｒアゴニストおよび甲状腺ホルモンの組み合わせでの筋肉障害の治療

Also Published As

Publication number Publication date
EP1653939A2 (en) 2006-05-10
AU2004263156A1 (en) 2005-02-17
AU2004263156B2 (en) 2009-02-26
CA2535260A1 (en) 2005-02-17
WO2005013949A3 (en) 2005-09-15
WO2005013949A2 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
AU2004263156B2 (en) Method for treating cachexia with retinoid ligands
US20070185055A1 (en) Method for treating cachexia with retinoid ligands
US5807884A (en) Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
EP2538978B1 (en) Use of an ep4 receptor antagonist in the treatment of allergic contact dermatitis and psoriasis
JP5902619B2 (ja) Ｒｘｒアゴニスト化合物および方法
CN1177586C (zh) 普拉克索作为神经保护剂的用途
CN100356922C (zh) 囊性纤维化跨膜传导调节因子蛋白抑制剂及其用途
KR101776337B1 (ko) 모발 관련 증상의 치료 방법
EP3644989A1 (en) Compositions and methods for modulating hair growth
JP5927236B2 (ja) 乾癬を予防または低減する方法
AU2019418584A1 (en) Compositions and methods for modulating hair growth
JP2000256194A (ja) 核内レセプタ作動薬およびその効果増強剤
JP2009537540A (ja) 化学療法および／または放射線療法の副作用を処置するためのｒａｒアンタゴニストまたはｒａｒインバースアゴニストの使用
CN1947717A (zh) 治疗神经和非神经痛的方法
KR960041168A (ko) 베타-아드레날린 효능성 작용물질
EP2037736A1 (en) Methods for treating cystic kidney diseases
JPS643185B2 (enExample)
WO1990015606A1 (en) Cnqx and its analogs as therapeutics for degenerative neural diseases
US6562858B2 (en) Method for treating depression
JP2005523292A (ja) ペルオキシソーム増殖因子活性化受容体モジュレーター
CN1859846A (zh) 白屈菜赤碱、其类似物及其在治疗躁郁症和其他认知紊乱中的应用
JP2001172180A (ja) アポｂ分泌／ｍｔｐ阻害剤の使用
JP2001139491A (ja) ａｐｏＢ分泌／ＭＴＰ阻害剤及び抗肥満剤の使用
KR100439384B1 (ko) 아포지단백질 비 분비/미소체 삼중글리세라이드 전이 단백질 저해제를 포함하는 약학 조성물
US20070167509A1 (en) Use of phenserine and analogs to treat behavioral problems and improve trainability

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070731

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110412